Blood · 2014 · 108 citations · 35 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyPediatric LeukemiasMyd88-dependent SignalingMyeloid Differentiation Primary Response 88 Signaling
Mutations in Toll-like receptor (TLR) and myeloid differentiation primary response 88 (MYD88) genes have been found in chronic lymphocytic leukemia (CLL) at low frequency. We analyzed the incidence, clinicobiological characteristics, and outcome of patients with TLR/MYD88 mutations in 587 CLL patients. Twenty-three patients (3.9%) had mutations, 19 in MYD88 (one with concurrent IRAK1 mutation), 2 TLR2 (one with concomitant TLR6 mutation), 1 IRAK1, and 1 TLR5. No mutations were found in IRAK2 and IRAK4. TLR/MYD88-mutated CLL overexpressed genes of the nuclear factor κB pathway. Patients with TLR/MYD88 mutations were significantly younger (83% age ≤50 years) than those with no mutations. TLR/MYD88 mutations were the most frequent in young patients. Patients with mutated TLR/MYD88 CLL had a higher frequency of mutated IGHV and low expression of CD38 and ZAP-70. Overall survival (OS) was better in TLR/MYD88-mutated than unmutated patients in the whole series (10-year OS, 100% vs 62%; P = .002), and in the subset of patients age ≤50 years (100% vs 70%; P = .02). In addition, relative OS of TLR/MYD88-mutated patients was similar to that in the age- and gender-matched population. In summary, TLR/MYD88 mutations identify a population of young CLL patients with favorable outcome.
35
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner, Stephan Stilgenbauer, Axel Benner et al. · New England Journal of Medicine · 2000 · 3.3K citations
Life Sciences, Genetics, Oncology +17
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Terry J. Hamblin, Zadie Davis, Anne Gardiner et al. · Blood · 1999 · 2.7K citations
Life Sciences, Genetics, Oncology +11